Abstract |
The live attenuated vesicular stomatitis virus-vectored Ebola vaccine rVSV-ZEBOV is currently undergoing clinical trials in West Africa. The vaccine is to be stored at -70°C or less. Since maintaining the cold chain is challenging in rural areas, the rVSV-ZEBOV vaccine's short-term and long-term stability at different temperatures was examined. Different dilutions were tested since the optimal vaccine dosage had not yet been determined at the start of this experiment. The results demonstrate that the original vaccine formulation was stable for 1 week at 4°C and for 24 hours at 25°C. The stability of the vaccine was compromised by both high temperatures and dilution.
|
Authors | Marianne Arnemo, Sara Sofie Viksmoen Watle, Kristin Merete Schoultz, Kirsti Vainio, Gunnstein Norheim, Vasee Moorthy, Patricia Fast, John-Arne Røttingen, Tor Gjøen |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 213
Issue 6
Pg. 930-3
(Mar 15 2016)
ISSN: 1537-6613 [Electronic] United States |
PMID | 26563239
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail [email protected]. |
Chemical References |
|
Topics |
- Animals
- Chlorocebus aethiops
- Ebola Vaccines
(chemistry)
- Hydrogen-Ion Concentration
- Temperature
- Time Factors
- Vaccine Potency
- Vero Cells
|